The purpose of this announcement is to conclude drug rebate agreements in accordance with § 130c (1) SGB V for the active ingredient(s) referred to in point II.1.1). This does not involve the award of public contracts within the meaning of Directive 2014/24/EU or Sections 97 et seq. of the Act against Restraints of Competition (GWB). Any pharmaceutical entrepreneur can become a contractual partner in accordance with § 4 para. 18 AMG. According to the case law of the European Court of Justice, such approval procedures are not necessarily subject to public procurement law, as there is no competition due to the lack of a selection decision. The announcement serves as an invitation to conclude discount agreements with conditions that apply equally to all contractual partners and are not dispositive, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point named under I.3).

The earliest start date of the contract is 01.03.2024, provided that the signed contract and the required declarations have been received by the contact point designated under I.3) by 07.02.2024. This is referred to in IV.2.2). In the event of later receipt, the contract shall commence on the 1st of the month following the month in which the signed contract and the required declarations or evidence are received by the contact point referred to in I.3), provided that receipt is made by the 5th of each month; otherwise the 1st of the month after next. The contracts terminate automatically, without the need for termination, as soon as contracts are concluded for the active substance(s) or the active ingredient combination(s) within the framework of an award procedure. The contracts end on 28.02.2026.